Sequencing Anti-EGFR Therapy in mCRC

Publication
Video
Supplements And Featured PublicationsMy Treatment Approach: Colorectal Cancer
Volume 1
Issue 1

The importance of aligning second-line treatment decisions with patient goals in metastatic colorectal cancer, and the benefits of treating patients with biweekly cetuximab, especially during the COVID-19 pandemic.

Zev A. Wainberg, MD: When we’re talking about someone with second-line disease, who hasn’t received an EGFR inhibitor, in the United States we tend to use FOLFIRI [5-fluorouracil, leucovorin, irinotecan]. If I haven’t used an EGFR inhibitor by now, I would use it then in left-sided RAS wild-type tumor patients. As you know, the response rate in a very large series, CALGB 80405, was only 10% or 15%. There’s a huge drop-off from the first-line to second-line therapy response rate in colon cancer. But the same rules apply. In essence, the way I see it is the FDA allows us to use these new dosing schedules in both first or second line with some degree of comfort.

Jaffer Ajani, MD: Also, patient convenience is a big thing. We hardly ever talk about the burden on the patient and caregivers: economic distress and loss of wages.

Zev A. Wainberg, MD: Taking a day off work and coming in for weekly infusions. Especially during COVID-19, which has accelerated a lot of the way we think about it. I agree with you, Jaffer. We’re not just asking someone to come in, we’re asking someone and their partner and their caregiver to come in once a week. It meant that the poor caregiver had to wait in the parking lot or around the corner. Fortunately, COVID-19 is getting much better, but we should keep that in mind. We should think about the inconveniences. I agree with you about that.

Jaffer Ajani, MD: COVID-19 certainly complicates the matter, but this still is a big burden on the family, and it would be easier for them to come every 2 weeks instead of coming weekly.

Transcript Edited for Clarity

Related Videos
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Rona Yaeger, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Richard Kim, MD, Moffitt Cancer Center
James Yu, MD,
Rona Yaeger, MD
Sebastian Stintzing, MD